A case report describes cholestatic liver injury during atezolizumab therapy for EGFR-mutant combined small cell lung cancer, ...

From diagnosis to treatment response, race and sex differences in PBC may reflect ongoing health disparities that remain to ...

The share of support for each candidate in the 15 most recent polls. About this data Note: The candidates shown are those who have gained the most support in recent polls. Some polls didn’t include ...

The 5-year survival rates after liver transplantation are similar for patients with PBC and primary sclerosing cholangitis.

(Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic ...

AGA and AASLD offer six recommendations for the diagnosis and management of PBC: Use SP100 and GP210 antibodies to help diagnose suspected PBC in those who test negative for antimitochondrial ...

US gastroenterology and liver disease associations issued joint guidelines on diagnosing and treating primary biliary ...

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...

Gilead Sciences, Inc. announced that it will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver ...

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...

Year-to-date total sales growth of 24.6% at CER1, or 23.0% as reported, with the core portfolio2 achieving sales growth of 24.2%1Further upgraded ...

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward ...